Kornimate/medical-research-clean huggingface dataset:
light sedation pressure support

Conditions: ARDS, Human

Summary: sedation may have many drawbacks in icu patients: cardiovascular, neurologic, muscular. light sedation and pressure support ventilation is feasible in ards patients. however spontaneous breathing can lead to high transpulmonary pressure. the goal of the study is to measure transpulmonary pressure before sedation decrease and after stabilization. the main endpoint is transpulmonary pressure less than 24 cmh2o.


Eligibility criteria:
inclusion criteria: * ards (berlin definition) * social insurance exclusion criteria: * neuromuscular disorders * pregnancy * need for muscular paralysis * need for deep neurosedation * more than 24hrs of artificial ventilation * cystic fibrosis
antibiotic footprint thailand - pilot questionnaire study

Conditions: Antibiotic Usage

Summary: antimicrobial-resistant bacterial infection is an important cause of death in thailand and in other countries worldwide. increasing use of antibiotics in both animals and humans is one of the main drive that increase the incidence of antimicrobial resistant bacteria in human, animals and environment. national action plan for combating antibiotic-resistant bacteria aimed to have general population taking antibiotics less than 20% when they have common cold or diarrheal symptoms. however, there is little accurate information about behaviors of thai people. most studies were conducted in hospitals, clinics or pharmacy. therefore, it did not include behaviors of those who had symptoms but did not present at hospitals, clinics or pharmacy. in this study, the investigators aim to use questionnaire to thai adult population to ask for the the amount of antibiotic used and the periods they had symptoms of common cold or diarrhea over one year period of year 2017. the main aim is to estimate the total antibiotic usage per human population, and plan for the study in the future.


Eligibility criteria:
inclusion criteria: the participant may enter the study if all of the following apply: 1. participant is willing and able to give informed consent for participation in the study. 2. male or female, aged 18 years or above. 3. living in thailand (staying in thailand more than 6 months per year) exclusion criteria: none

Keywords: antimicrobial-resistant bacterial infection questionaire
end-stage renal disease (esrd) pilot study

Conditions: Renal Dialysis

Summary: the purpose of this study is to investigate the safety of two different doses of a drug called bay1213790 and how well it is tolerated in patients with end-stage renal disease (esrd) undergoing hemodialysis (hd). approximately 40, with up to 60 study patients will take part in the study.


Eligibility criteria:
inclusion criteria * male and female patients between 18 and 80 years of age. * esrd on hemodialysis (including hemodiafiltration) for at least 3 months * life expectancy of \> 6 months * women of non-childbearing potential exclusion criteria: * high risk for clinically significant bleeding * acute renal failure * planned major surgery in the next 7 months from randomization * concomitant use of oral anticoagulant therapy or antiplatelet therapy * documented thrombotic event in the past 6 months

Keywords: end-stage renal disease patients undergoing hemodialysis
study to evaluate the safety and efficacy of virazole® in hospitalized adult participants with respiratory distress due to covid-19

Conditions: COVID19

Summary: this study is a phase 1, open label, non-randomized, two-arm interventional clinical trial to evaluate the safety and efficacy of virazole® in hospitalized adult patients who have tested positive for covid-19 and, as a result, have significant respiratory distress (pao2/fio2 ratio \<300 mmhg).


Eligibility criteria:
inclusion criteria: 1. male or non-pregnant female ≥ 18 years of age. 2. willing and able to provide written informed consent (or provided by a proxy). 3. currently hospitalized with laboratory confirmed covid-19 novel coronavirus infection. 4. pao2/fio2 ratio \<300 mmhg. 5. illness of any duration, and at least one of the following: * radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or * clinical assessment (evidence of rales/crackles on exam) and spo2 ≤94% on room air, or * requiring mechanical ventilation and/or supplemental oxygen. 6. once released from the hospital, women of childbearing potential (wocbp) and all men must agree to use at contraception methods for 9 months. exclusion criteria: 1. pregnant or breast feeding. 2. respiratory distress for reasons other than covid-19 infection (e.g., congestive heart failure (chf), bacterial pneumonia, etc.). 3. presence of secondary bacterial pneumonia. 4. presence of significant pulmonary fibrosis. 5. hypotension (need for hemodynamic pressors to maintain blood pressure). 6. greater than 7 days on mechanical ventilation. 7. anemia defined as hemoglobin or rbc \<75% of the institutional lower limit of normal for race, age and gender. 8. history of copd or bronchospasm prior to covid-19 infection. 9. history of hypersensitivity to ribavirin. 10. any condition that could cause noncompliance with treatment or may otherwise contraindicate the subject's participation in the study 11. subject is currently participating in any drug or device clinical investigation. 12. subject has received an investigational agent or approved drug that, in the investigator's judgement, may have a chemical or pharmacological interaction with virazole if administered within 5 half-lives or 30 days of the baseline visit.
botulinum toxin a single blind split-face randomized pilot study

Conditions: Facial Rhytids

Summary: a 16-week single-blind, split-face, randomized study. each patient served as their own control, receiving onabotulinumtoxina and abobotulinumtoxina randomized to either the left or right side of the face. patients received intradermal btxa injections at week 0 and intramuscular btxa injections at week 2. the objective is to examine the effectiveness of intradermal botulinum toxin type a (btxa) injection in improving skin texture and midface lift while reducing pore size and sebum production, as well as investigate the differences in effectiveness between onabotulinumtoxina and abobotulinumtoxina using intradermal and intramuscular injection methods.


Eligibility criteria:
inclusion criteria: * female subjects between ages of 35 to 65 years (inclusive) who exhibit static wrinkles in the following areas: glabella (forehead frowns), periorbital area (crows feet). static wrinkles in additional areas of the face are also acceptable. * subject is willing to maintain the same skin care regimen throughout the study and has already maintained this skin care regime for 4 weeks prior to baseline. * the subject is able to comply with study procedures and instructions and is committed to attend all study visits within the given timelines. * subject is judged to be a good candidate by study nurse upon identification of dynamic and/or static wrinkles in the areas of movement, and with a moderate amount of skin laxity. * subject is willing to use contraception * a signed informed consent form by a subject able to give consent, prior to any study procedures are performed. exclusion criteria: * sensitivity and/or contraindications to botulinum toxin a other ingredients contained in the botulinum toxin a products. * any medical condition, in the opinion of the investigator, that would interfere with safety or any study procedures (e.g. auto-immune disease, history of severe allergies, hypertrophic scars, immunotherapeutic treatment, inflammatory or infectious complaints at injection sites, unable to give consent) * treatment with botulinum toxin a injections in the neck or face within 1 year of baseline treatment * treatment with facial fillers less than 1 year prior to baseline * females of childbearing potential who are pregnant, breastfeeding or plan to get pregnant during the course of the study. * previous treatment with lasers, ultrasound technology or radio frequency on the face and/or neck within 1 year prior to baseline. * treatment with accutane (isotretinoin) or other oral medications for acne during 1 year prior to baseline. * the use of anti-aging products containing retinol * known allergy to cow's milk protein

Keywords: botulinum toxin type a, intradermal
endogenous endophthalmitis in the inpatient setting

Conditions: Endophthalmitis

Summary: the purpose of this study is to determine the rate of endogenous endophthalmitis in patients admitted to stanford hospital with a systemic infection and positive blood cultures, as this may improve the clinical care of this population of patients.

some patients admitted to the hospital have blood-borne infections. occasionally, these blood infections can end up inside the eye and cause an infection inside the eye (called endogenous endophthalmitis). prior to modern and rapid treatment of systemic infections, the rate of endogenous endophthalmitis was reported to be 37% in 1982. by 1997, the rate was reported to be 2.8%. this study aims to determine the rate of endogenous endophthalmitis at stanford hospital in the modern medical era in that our rates may be different as those reported in the literature. this potential difference may be a reflection of treatment protocols and antibiotics currently in use at stanford hospital.

Eligibility criteria:
inclusion criteria:all patients admitted to stanford hospital that have a systemic blood-borne infection and on which an ophthalmology consult to rule out endogenous endophthalmitis is performed will be included in the study. exclusion criteria:none
pne with therapeutic exercises on pain intensity in lumbar radiculopathy

Conditions: Lumbar Radiculopathy

Summary: there is lack of structured pain neuroscience education in patients with lumber radiculopathy. previously researches were done on pain neuroscience education before surgery of lumber radiculopathy. however this study will provide structured educational plan about pain neuroscience education along with therapeutic exercises to positively influence pain knowledge, dysfunction, and fear avoidance, limitation in movement and healthcare utilization in patients who have diagnosed with lumbar radiculopathy and don't want to undergo surgery.

radicular pain or radiculopathy, defined as spinal nerve root dysfunction causing dermatomal discomfort and paresthesia's, myotome weakness, and/or reduced deep tendon reflexes, is frequently associated with axial spine pain. it affects both men and women and is believed to impact 3 to 5 percent of the population. radiculopathy is pain that radiates down the legs and is described as electric, burning, and acute pain. radiculopathy is most caused by irritation of a specific nerve, which can occur anywhere along the nerve and is most often caused by a compressive force. it could be caused by bulging or herniated discs, facet or ligamentous hypertrophy, spondylolisthesis, or even neoplastic or infectious diseases. lr is the second leading cause of disability according to a research published by global burden of disease (gbd).pain neuroscience education (pne), also known as therapeutic neuroscience education (tne), is a series of instructional sessions for patients that cover the neurobiology and neurophysiology of pain, as well as how the nervous system processes pain. pne alters the way a patient perceives pain at first. for example, a patient may have assumed that damaged tissues were the source of their pain; yet, after learning more about pain neurophysiology, the patient realises that pain may not accurately reflect tissue health and instead be caused by extra-sensitive nerves.

Eligibility criteria:
inclusion criteria: * presence of lumbar radiculopathy ( disc bulge , disc herniation , lumbar stenosis, disk dehydration(13) * medication. (patient already on prescriptions, using medicines) * duration of low back pain as the main symptom for at least 3 months exclusion criteria: * the presence of chronic-pain-related conditions (e.g. fibromyalgia, chronic fatigue syndrome.) * pregnancy * patients on treatment with alternative therapies. * patients with associated pathologies that make it impossible to perform a physical exercise program (myopathies, neurological diseases with significant impairment of functionality
comparison of the panax ginseng + associations to ginkgo biloba in the treatment of cognitive function disorders

Conditions: Memory Deficit

Summary: the purpose of this study is to evaluate the efficacy and safety of two different drugs in the treatment of patients diagnosed with memory difficulties and a decline in cognitive function. this is a parallel distribution: a group of patients will be treated with a combination panax ginseng + ginkgo biloba + multivitamin + polyminerals (ems), and another group with ginkgo biloba (tebonin ®).

study design: * multicenter, phase iii, double-blind, randomized entry of patients, prospective and comparative * the duration of the study: 60 days * 3 visits (days 1, 30 and 60) * evaluate the effectiveness of the association * evaluate the safety of the combination * adverse events evaluation

Eligibility criteria:
inclusion criteria: 1. patients of any race, sex, aged 18-60 years; 2. patients presenting two or more symptoms associated with disorders of cognitive function such as memory impairment, poor concentration, depressed mood, decreased mental capacity, provided they score value is below 24 in the evaluation of the psychometric test (mini test-mental and wms-r logical memory); 3. consent of the patient (signature of the ic); 4. patients are able to read and write; 5. "washout" of at least two weeks of the start of the study, in case of use of multivitamins or any other medication for symptomatic treatment of disorders of cognitive function. 6. women of childbearing potential must submit βhcg negative serum; 7. patients are able to understand and carry out the study procedures; exclusion criteria: 1. patients with hypersensitivity to the components of the formula; 2. patients who are making use of levodopa or salicylates; 3. routine use of medications that alter cognitive functions such as barbiturates, anticonvulsants, benzodiazepines, neuroleptics, alcohol and illicit drugs; 4. pregnant or lactating women; 5. participation in another clinical trial with investigational medication in the last 3 months; 6. patients with prior knowledge of infectious disease; 7. patients who are taking other multivitamins or any other medications for the symptomatic treatment of disorders of cognitive function, at least two weeks prior to study initiation. 8. patients with organic dementias such as alzheimer's, pick's disease, creutzfeldt-jacob disease, huntington's, parkinson's disease, dementia caused by human immunodeficiency virus (hiv), hypothyroidism, vascular dementia (arteriosclerotic dementia), dementia senile among others;

Keywords: disorders of cognitive function
naltrexone for medication compliance among hiv-infected men with alcohol use disorder

Conditions: HIV; Alcohol Use Disorder

Summary: this study will recruit 159 hiv-infected men with alcohol use disorders (auds). men will be randomized to receive either oral naltrexone for the treatment of alcohol use disorder or placebo. men with acute, recent or established hiv infection will receive antiretroviral treatment (art) and be randomized to oral naltrexone or placebo. the purpose of this study is to see whether use of oral naltrexone improves medication compliance, and therefore hiv viral load suppression, among men with alcohol use disorder. the study will also assess the impact of oral naltrexone on alcohol use behaviors in this population.


Eligibility criteria:
inclusion criteria: * meets dsm-iv criteria for alcohol dependence or problem drinking. * age 18 years and older * confirmed hiv infection, either through positive hiv antibody or detectable hiv-1 rna level. * no participation in pharmacotherapy trial in the previous 30 days * not pregnant exclusion criteria: * unable to provide informed consent * verbally or physically threatening to research staff * unable to communicate in spanish * pending trials for a felony * childs-pugh class c cirrhosis * grade 3 hepatitis (lfts \> 5x normal) * receiving opioid prescription narcotics or has pain syndrome necessitating future use of opioid prescription narcotics.
modifications of immune microenvironment induced by neoadjuvant chemotherapy in triple-negative bc

Conditions: Triple Negative Breast Cancer

Summary: the prescription of neoadjuvant chemotherapy becomes a standard in women with her2-positive or triple-negative breast cancer and allows a complete histological response (pcr) which represents a prognostic factor for survival. . the problem for patients who are not pcr is that they are currently receiving non-personalized adjuvant systemic treatment. the identification of biomarkers present in the residual disease would be a criterion to guide the choice of post-neoadjuvant adjuvant systemic treatment, in order to personalize it. at the present time, there is no published study describing extensively the immune micro-environment (me) in breast cancer, whether before or after chemotherapy, nor its modification induced by chemotherapy. the team therefore propose to study in a retrospective and monocentric series, the modifications of the immune me induced by a "standard" neo-adjuvant chemotherapy in patients with triple-negative cs, whether they are in complete histological response or not (n = twice 50). the main objective of this project is to describe the changes in the immune me of triple-negative breast cancers induced by neoadjuvant chemotherapy for all patients (in pcr or not): * quantification of tils and subtypes of tils (cd4 and cd8) * expression of the three immune checkpoints that are pdl1, tim3 and lag3 * describe the organization of the immune system (immunostaining on the same slide of the pdl1, tim3 and lag3 immune checkpoints)

retrospective and monocentric translational study carried out on patients treated at the iuct-oncopole by neoadjuvant chemotherapy (sequential treatment fec100 or ec100 then taxane, paclitaxel weekly for the most part) for a triple-negative cs between 2012 and 2018. we have the microbiopsy of the primary tumor preserved in ffpe and the operating room preserved in ffpe. we have all the clinical data for the diagnosis and monitoring of these patients, already entered into a database. the search for a brca germline mutation is available in most patients if indicated for an oncogenetic consultation. biomarkers analysis : * tils account according to salgado et al. before and after neoadjuvant chemotherapy * ihc ck5-6 and egfr then ra if the first two are negative to characterize triple negative tumors in "basal-like" and "non-basal-like" * ihc cd3 (labeling of t lymphocytes) * ihc cd4, cd8 and foxp3 before and after neoadjuvant chemotherapy * pdl1, tim3 and lag3 multiplex ihc before and after neoadjuvant chemotherapy * labeling of tumor cells: ae1 / ae3 * use of markings for exploratory analyzes: cd68 (macrophages), cd39 (marker of lymphocyte exhaust

Eligibility criteria:
inclusion criteria: * samples from triple negative bc patients, patients treated by neoadjuvant chemotherapy ( fec or ec than taxanes) patients consent to use their samples. exclusion criteria: * samples not available before or after neoadjuvant chemotherapy

Keywords: post neo adjuvant therapy immune micro environment biomerker chacterization
chronic obstructive pulmonary disease case finding in community-pharmacies by spirometry

Conditions: Chronic Obstructive Pulmonary Disease

Summary: chronic obstructive pulmonary disease (copd) is a prevalent disease. in the investigators country, underdiagnosis has been estimated in around 80% of subjects. early detection is done mainly in primary care but due to actual situation new alternatives have been proposed to decrease underdiagnosis. this present study promote by a multidisciplinary research team (respiratory medicine, primary care, nurse and pharmacist) raise the objective of evaluate the effect of a copd case finding program guide by spirometry in community-pharmacies. from the results of a pilot-study conducted in 13 community-pharmacies in barcelona, in which the investigators showed the feasibility of spirometry in community-pharmacies for the early detection of copd, the investigators have design a second phase to evaluate the effect of this strategy. 100 barcelona's community-pharmacies during 6 months will select high risk customers and will conduct a spirometry in agreement with the design protocol. 3600 spirometries is the establish objective. participants hospitals will train pharmacist in spirometry and also control spirometry quality daily by a telematic pathway. spirometry results will be evaluate in terms of effect and costs. the investigators will also evaluate the impact of this program in the health system by numbers of subjects diagnosed and follow up in primary care.


Eligibility criteria:
inclusion criteria: * age over 40 years. * current or former smoker * chronic respiratory symptoms(cough, shortness of breath, expectoration) exclusion criteria: * previous diagnosed chronic lung disease * use of inhalers

Keywords: copd pharmacy spirometry case finding
study of efficacy and safety of abo809 in healthy participants

Conditions: Cryptosporidium Infection, Cryptosporidiosis

Summary: the purpose of this phase i controlled human infection model (chim) study was to determine if oral administration of a good manufacturing practice (gmp) supply of cryptosporidium parvum oocysts (abo809) to healthy volunteers resulted in a cryptosporidium infection and diarrheal illness. the study measured fecal oocysts (parasitological endpoint) as well as diarrhea and associated signs and symptoms (clinical endpoint).

this study was funded by the wellcome trust. this phase 1 cryptosporidium controlled human infection model (chim) study employed a single-center, open-label design to characterize the incidence of infection and associated symptoms following the administration of single doses of cryptosporidium parvum oocysts (ce). healthy volunteers were enrolled in cohorts of approximately 10 participants who received abo809 on the same day (day 1). the study consisted of three sequential cohorts which were dosed one after the other for a total of 30 participants. a dose level group received the same abo809 dose and could be comprised of multiple cohorts. the first dose level group started with a cohort of 10 participants who received abo809 at a dose of 1x10\^4 oocysts. the study continued to enroll participants in the same dose level group if the desired incidences of infection and diarrheal illness were observed, up to a total of approximately 30 participants. if the desired incidences of infection and diarrheal illness were not observed, a new dose level group, receiving abo809 at a dose of 1x10\^6 oocysts, could be initiated. if needed to optimize the model, intermediate abo809 doses could be evaluated.

Eligibility criteria:
inclusion criteria: * demonstrated understanding of cryptosporidium disease, safety measures and transmission risks * good health * ability to communicate well with the investigator exclusion criteria: - history of cryptosporidium infection, gastrointestinal conditions (including diarrheal syndromes, gastroenteritis and gastrointestinal tract surgery), immunodeficiency, infections, significant medical concerns, hypersensitivity to nitazoxanide or other specified antibiotics. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: controlled human infection model, safety, tolerability, healthy volunteers, cryptosporidiosis, abo809